Literature DB >> 15640257

High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status.

Renato Fanchin1, Joëlle Taieb, Daniel H Mendèz Lozano, Béatrice Ducot, René Frydman, Jean Bouyer.   

Abstract

BACKGROUND: Our aim was to compare the intercycle reproducibility of serum anti-Mullerian hormone (AMH) measurements with that of other markers of ovarian follicular status.
METHODS: Forty-seven normo-ovulatory, infertile women underwent serum AMH, inhibin B, estradiol and FSH measurements and early antral follicle (2-12 mm in diameter) counts by transvaginal ultrasound on cycle day 3 during three consecutive menstrual cycles. Reproducibility of measurements was estimated using intra-class correlation coefficient (ICC) calculation. We also assessed the number of replicate measurements theoretically needed to reach satisfactory reliability of results.
RESULTS: Serum AMH showed significantly higher reproducibility (ICC, 0.89; 95% confidence interval, 0.83-0.94) than inhibin B (0.76; 0.66-0.86; P < 0.03), estradiol (0.22; 0.03-0.41; P < 0.0001) and FSH levels (0.55; 0.39-0.71; P < 0.01), and early antral follicle counts (0.73; 0.62-0.84; P < 0.001), and reached satisfactory reliability with a single measurement.
CONCLUSIONS: The improved cycle-to-cycle consistency of AMH as compared with other markers of ovarian follicular status is in keeping with its peculiar production by follicles at several developmental stages and further supports its role as a cost-effective, reliable marker of ovarian fertility potential.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15640257     DOI: 10.1093/humrep/deh688

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  56 in total

1.  Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).

Authors:  Megan E B Clowse; Susannah C Copland; Tsung-Cheng Hsieh; Shein-Chung Chow; Gary S Hoffman; Peter A Merkel; Robert F Spiera; John C Davis; W Joseph McCune; Steven R Ytterberg; E William St Clair; Nancy B Allen; Ulrich Specks; John H Stone
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-12       Impact factor: 4.794

2.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

Review 3.  Ovarian reserve evaluation: state of the art.

Authors:  Bruno Ramalho de Carvalho; Ana Carolina Japur de Sá Rosa e Silva; Júlio César Rosa e Silva; Rosana Maria dos Reis; Rui Alberto Ferriani; Marcos Felipe Silva de Sá
Journal:  J Assist Reprod Genet       Date:  2008-08-05       Impact factor: 3.412

4.  Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2-6 mm).

Authors:  Abbas Aflatoonian; Homa Oskouian; Shahnaz Ahmadi; Leila Oskouian
Journal:  J Assist Reprod Genet       Date:  2009-06-20       Impact factor: 3.412

5.  Impact of CD4+ lymphocytes and HIV infection on Anti-Müllerian Hormone levels in a large cohort of HIV-infected and HIV-uninfected women.

Authors:  Rebecca Scherzer; Peter Bacchetti; Geralyn Messerlian; Johanna Goderre; Pauline M Maki; David B Seifer; Kathryn Anastos; Roksana Karim; Ruth M Greenblatt
Journal:  Am J Reprod Immunol       Date:  2014-10-23       Impact factor: 3.886

6.  Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles.

Authors:  MaryFran Sowers; Daniel McConnell; Katherine Gast; Huiyong Zheng; Bin Nan; Jenifer D McCarthy; John F Randolph
Journal:  Fertil Steril       Date:  2009-12-06       Impact factor: 7.329

7.  Disruptions in ovarian function are related to depression and cardiometabolic risk during premenopause.

Authors:  Maria E Bleil; Joyce T Bromberger; Melissa D Latham; Nancy E Adler; Lauri A Pasch; Steven E Gregorich; Mitchell P Rosen; Marcelle I Cedars
Journal:  Menopause       Date:  2013-06       Impact factor: 2.953

8.  Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patients.

Authors:  Cheng-Hsuan Wu; Yu-Ching Chen; Hsin-Hung Wu; Jyuer-Ger Yang; Yu-Jun Chang; Horng-Der Tsai
Journal:  J Assist Reprod Genet       Date:  2009-07       Impact factor: 3.412

9.  Does accelerated reproductive aging underlie premenopausal risk for cardiovascular disease?

Authors:  Maria E Bleil; Steven E Gregorich; Daniel McConnell; Mitchell P Rosen; Marcelle I Cedars
Journal:  Menopause       Date:  2013-11       Impact factor: 2.953

10.  Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk.

Authors:  Joanne F Dorgan; Frank Z Stanczyk; Brian L Egleston; Lisa L Kahle; Christiana M Shaw; Cynthia S Spittle; Andrew K Godwin; Louise A Brinton
Journal:  J Natl Cancer Inst       Date:  2009-10-09       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.